Heterologous prime-boost immunization with CoronaVac and Convidecia

Jingxin Li; Lihua Hou; Xiling Guo; Pengfei Jin; Shipo Wu; Jiahong Zhu; Hongxing Pan; Xue Wang; Zhizhou Song; Jingxuan Wan; Lunbiao Cui; Junqiang Li; Xuewen Wang; Lairun Jin; Jingxian Liu; Fengjuan Shi; Xiaoyu Xu; Yin Chen; Tao Zhu; Wei Chen; Fengcai Zhu.
Preprint en Inglés | PREPRINT-MEDRXIV | ID: ppmedrxiv-21263062

Documentos relacionados

  1. Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
  2. The 6-Month Antibody Durability of Heterologous Convidecia Plus CoronaVac and Homologous CoronaVac Immunizations in People Aged 18-59 Years and over 60 Years Based on Two Randomized Controlled Trials in China.